Tim Kelly chief technology officer Caribou Biosciences Tim Kelly to lead Caribou s technical operations strategy and execution -- Tim Kelly to lead Caribou s technical operations strategy and execution -- -- CB- ANTLER Phase trial initial dose expansion data and RP D to be disclosed Q Caribou plans to initiate pivotal Phase trial in L LBCL by YE --...
Globe News Wire
Preliminary Total Revenue of million to million Crysvita Revenue of million to million and Dojolvi revenue of million to million expected Total Revenue guidance between million to million Crysvita revenue of million to million and Dojolvi revenue of million to million Year-end cash balance of approximately million and guidance for net cash used in operations expected to be less than...
- Positive data from -patient head-to-head trial versus Shingrix shows amezosvatein met the primary immunogenicity endpoint eliciting a robust immune response non-inferior to Shingrix including a vaccine response rate -- Amezosvatein also met the primary safety endpoint with lower local and systemic adverse events in this trial compared to Shingrix -- Amezosvatein to enter global Phase trials in SEATTLE Jan...
HAGENS BERMAN NATIONAL TRIAL ATTORNEYS Encourages Beauty Health Company SKIN Investors with Substantial Losses to Contact Firm Before Jan th DeadlineSAN FRANCISCO Jan GLOBE NEWSWIRE -- Hagens Berman urges The Beauty Health Company NASDAQ SKIN investors who suffered substantial losses to submit your losses now Class Period May Nov Lead Plaintiff Deadline Jan Visit www hbsslaw com investor-fraud SKINContact An...